Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E41.59 EPS (ttm)1.56 Insider Own0.04% Shs Outstand2.74B Perf Week1.79%
Market Cap177.87B Forward P/E15.55 EPS next Y4.18 Insider Trans-16.73% Shs Float2.73B Perf Month3.74%
Income4.35B PEG6.91 EPS next Q0.87 Inst Own76.10% Short Float0.55% Perf Quarter-1.41%
Sales39.93B P/S4.45 EPS this Y-10.00% Inst Trans0.29% Short Ratio1.68 Perf Half Y5.32%
Book/sh14.51 P/B4.47 EPS next Y8.67% ROA4.50% Target Price69.30 Perf Year15.13%
Cash/sh5.57 P/C11.66 EPS next 5Y6.02% ROE10.40% 52W Range55.10 - 66.80 Perf YTD10.28%
Dividend1.88 P/FCF105.19 EPS past 5Y-7.00% ROI6.20% 52W High-2.81% Beta0.86
Dividend %2.90% Quick Ratio1.30 Sales past 5Y-3.70% Gross Margin67.70% 52W Low17.82% ATR0.74
Employees68000 Current Ratio1.60 Sales Q/Q1.30% Oper. Margin14.40% RSI (14)61.41 Volatility0.92% 1.22%
OptionableYes Debt/Eq0.71 EPS Q/Q39.30% Profit Margin10.90% Rel Volume0.41 Prev Close65.04
ShortableYes LT Debt/Eq0.59 EarningsMay 02 BMO Payout117.50% Avg Volume9.00M Price64.92
Recom2.30 SMA201.90% SMA502.49% SMA2003.60% Volume3,667,635 Change-0.18%
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-27-16Downgrade BofA/Merrill Buy → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $64 → $66
Nov-24-15Initiated Berenberg Hold
Nov-17-15Reiterated Argus Buy $70 → $65
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
May-27-17 08:40AM  Top Presentations to Look for at ASCO 24/7 Wall St.
May-26-17 12:44PM  Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others Zacks
12:10PM  Cambridge biotech Enumeral faces uncertain future as cash dries up American City Business Journals
10:20AM  UnitedHealth's (UNH) Business Unit Collaborates with Merck Zacks
09:42AM  Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer Zacks
09:30AM  The Zacks Analyst Blog Highlights: Merck, 3M, United Technologies, Ford Motor and Humana Zacks
07:47AM  Here's How the FDA Just Helped Trump Deliver on a Big Promise Motley Fool
07:37AM  Changes in Sanofis Valuation after Its 1Q17 Earnings Market Realist
May-25-17 02:28PM  New Stock Research Reports for Merck, 3M and United Technologies Zacks
02:00PM  Optum and Merck Collaborate to Advance Value-Based Contracting of Pharmaceuticals Business Wire
09:45AM  Major Pharma Short Interest Surges 24/7 Wall St.
09:24AM  Radius Health Osteoporosis Drug Positive in Phase III Study Zacks
09:06AM  Performance of Mercks Animal Health Segment in 1Q17 Market Realist
08:15AM  Blog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common Biomarker Instead of the Location of the Tumor Accesswire
08:00AM  Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau Business Wire
07:35AM  Mercks Immunology and Cardiovascular Franchise in 1Q17 Market Realist
May-24-17 10:36AM  Performance of Mercks Diabetes Portfolio in 1Q17 Market Realist
10:28AM  AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk Zacks
10:18AM  Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers Zacks
09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
07:36AM  1Q17 Performance of Keytruda, Mercks Blockbuster Drug Market Realist
12:26AM  FDA Approves Mercks Keytruda to Treat Cancers With Genetic Defects The Wall Street Journal
May-23-17 06:20PM  FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects The Wall Street Journal
06:01PM  FDA clears Merck's Keytruda based on cancer genetics, not location Reuters
05:21PM  Merck Presents Phase II Data on Chronic Cough Candidate Zacks
04:34PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer Business Wire
03:36PM  The FDA just took an entirely new approach to approving a cancer drug Business Insider
03:33PM  FDA clears Merck's Keytruda for cancer patients with certain biomarkers Reuters
01:19PM  Merck Announces Third-Quarter 2017 Dividend Business Wire
11:35AM  Merck & Co.s Segmental Performance in 1Q17 Market Realist
10:05AM  Why Merck & Co. Continued to Grow in 1Q17 Market Realist
08:14AM  A Close Look at Merck & Co.s Valuation after 1Q17 Earnings Market Realist
08:13AM  UK competition watchdog accuses Merck of obstructing biosimilars Reuters
06:55AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Business Wire
06:05AM  Merck & Co Faces Financial Hit From U.K. Regulator Over Drug Pricing TheStreet.com
06:00AM  These Big Drug Stocks May Cure the Trump Blues Investopedia
05:01AM  UK competition watchdog accuses Merck of obstructing biosimilars Reuters
May-22-17 04:47PM  Dow Jones Industrial Average And Dow Stocks: News And Analysis Investor's Business Daily
11:20AM  Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough Business Wire
09:06AM  Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings? Zacks
08:50AM  Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose Zacks
May-21-17 06:28PM  Higher rate of heart problems with Amgen osteoporosis drug in trial Reuters
03:02PM  3 Top Animal-Health Companies to Buy in 2017 Motley Fool
May-19-17 02:01PM  ETFs with exposure to Merck & Co., Inc. : May 19, 2017 Capital Cube
10:15AM  Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications Zacks
08:00AM  Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union Business Wire
04:00AM  100 Healthy Years - Are Kids Prepared? PR Newswire
May-18-17 06:21PM  US Market Indexes Higher on Thursday GuruFocus.com
04:50PM  The Hot Stock: Incyte Climbs Barrons.com
04:17PM  Merck's Keytruda gets two bladder cancer approvals from FDA MarketWatch
04:00PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer Business Wire
09:54AM  Merck & Co., Inc. :MRK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 Capital Cube
08:45AM  4 Large-Cap Drug Stocks To Buy Post Q1 Earnings Zacks
08:40AM  Merck & Co., Inc. breached its 50 day moving average in a Bearish Manner : MRK-US : May 18, 2017 Capital Cube
06:21AM  What to watch at ASCO cancer conference CNBC Videos
03:39AM  Merck KGaA CFO Believes in Value Based Pricing Bloomberg Video
03:29AM  Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings TheStreet.com
May-17-17 06:55PM  Merck says test shows Keytruda improves survival for bladder cancer patients Reuters
05:20PM  Merck, Incyte immunotherapy combination effective in lung cancer study Reuters
05:00PM  Merck, Incyte immunotherapy combination effective in lung cancer study Reuters
05:00PM  Merck says test shows Keytruda improves survival for bladder cancer patients Reuters
05:00PM  Data for KEYTRUDA® (pembrolizumab) Across 16 Types of Cancer from Mercks Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting Business Wire
02:16PM  Aduro Biotech, Merch Team on Cancer Drug Trial TheStreet.com
12:39PM  Eli Lilly: Worries Ahead In Patent Fight Barrons.com
09:43AM  5 Reasons Why Merck (MRK) is a Good Stock to Buy Now Zacks
May-16-17 06:22PM  Merck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case Reuters
12:17PM  Eli Lilly: Has This Bloom Begun To Wilt? Barrons.com
10:00AM  The Global Game Changers List 2017: Evan Spiegel, Anne Wojcicki And Other Business Leaders Reshaping The World Forbes
08:00AM  Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the American Diabetes Association Business Wire
May-15-17 08:15AM  Post Earnings Coverage as Merck's EPS Surged 40%; Raised Outlook Accesswire
May-12-17 06:04PM  Nasdaq Closes at 6121, Stocks Mostly Lower GuruFocus.com
05:00PM  Johnson & Johnson Analyst Day Yahoo Finance Video
01:39PM  UPDATE 3-Congo death signals new Ebola outbreak-ministry Reuters
11:25AM  Person dies of Ebola virus in Congo in first - Health Ministry Reuters
08:00AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceuticals and Merck & Co. Accesswire
06:23AM  Key AstraZeneca drug shown to reduce risk of death from lung cancer Reuters
May-11-17 03:13PM  Merck Can't Say How Good its Good News Is Bloomberg
02:02PM  Merck CEO: We're doing the right studies to make KeyTruda... CNBC Videos
11:52AM  Here's What The FDA Approval Of Keytruda Means For Merck, And For Bristol-Myers Benzinga
11:40AM  Why Big Pharma Is Not at Fault for Record Drug Spending 24/7 Wall St.
09:52AM  Has Merck Lucked Into A $10 Billion Drug? Forbes
09:30AM  The Zacks Analyst Blog Highlights: Merck, Barclays, Activision Blizzard, Blackstone and Tyson Foods Zacks
08:10AM  Merck stock rises 2.4% after new Keytruda lung cancer approval MarketWatch
07:52AM  FDA Approves Combining Mercks Keytruda With Chemotherapy in Lung Cancer Patients The Wall Street Journal
May-10-17 06:52PM  FDA Approves Combining Merck's Keytruda With Chemotherapy The Wall Street Journal
06:12PM  U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer Reuters
05:39PM  U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer Reuters
05:39PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression Business Wire
02:56PM  Roche Throws a New Wrinkle Into the IO Market Bloomberg
10:01AM  European Commission Grants Approval for Merck's New Pergoveris® Pen for Fertility Treatment CNW Group
09:00AM  Short Interest in Major Pharma Shrinks 24/7 Wall St.
May-09-17 09:56PM  Edited Transcript of MRK earnings conference call or presentation 2-May-17 12:00pm GMT Thomson Reuters StreetEvents
05:36PM  Merck & Co., Inc. Value Analysis (NYSE:MRK) : May 9, 2017 Capital Cube
10:29AM  Sanofi pegs U.S. drug price rises to below healthcare inflation Reuters
May-08-17 09:34AM  J&J: What's In Store At Next Week's Analyst Meeting Barrons.com
08:46AM  Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit Zacks
08:27AM  Merck & Co., Inc. breached its 50 day moving average in a Bullish Manner : MRK-US : May 8, 2017 Capital Cube
08:15AM  Blog Coverage: Merck Receives European Commission Approval for the Treatment of Hodgkin Lymphoma Accesswire
May-05-17 05:04PM  Dow 30 Stock Roundup: Apple, Merck Beat; Pfizer Misses on Revenues Zacks
04:37PM  Merck vs. Pfizer: Which Stock Looks Better Post-Earnings? Zacks
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has clinical collaboration agreement with Aduro Biotech, Inc. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise23.45133,9203,140,424642,797Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale65.03133,9208,709,286508,877Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Option Exercise23.456,080142,576514,957Nov 10 05:29 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale65.006,080395,200508,877Nov 10 05:29 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise41.5385,5233,551,946124,638Nov 08 11:51 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale60.0285,5235,133,33039,115Nov 08 11:51 AM
LAZARUS ROCHELLE BDirectorNov 02Option Exercise37.3520,000746,95024,594Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Option Exercise51.865,000259,3006,000Nov 02 04:54 PM
WENDELL PETER CDirectorNov 02Sale59.505,000297,5001,000Nov 02 04:54 PM
LAZARUS ROCHELLE BDirectorNov 02Sale59.0620,0001,181,2004,594Nov 02 04:54 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Option Exercise44.1940,8001,802,952128,973Oct 04 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HROct 03Sale62.0740,8002,532,58288,173Oct 04 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Option Exercise33.4939,2001,312,80839,200Sep 01 03:37 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 01Sale62.6139,2002,454,3080Sep 01 03:37 PM
Golestani ClarkEVP & Chief Info OfficerAug 10Sale63.033,000189,09014,083Aug 10 04:57 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Option Exercise36.85392,00014,446,600900,877Aug 05 05:48 PM
FRAZIER KENNETH CChairman, President & CEOAug 05Sale61.81392,00024,231,096508,877Aug 05 05:48 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 02Option Exercise0.005,150037,570Aug 03 02:51 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Option Exercise51.0227,6211,409,223550,098Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 05Sale58.0027,6211,602,018522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 05Sale57.9945,0002,609,33087,151Jul 05 12:56 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Option Exercise44.3050,0002,215,00050,000Jul 01 01:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Option Exercise40.7030,0001,221,000162,151Jul 01 01:13 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Option Exercise51.0232,3791,651,977554,856Jul 05 12:56 PM
FRAZIER KENNETH CChairman, President & CEOJul 01Sale58.0032,3791,877,982522,477Jul 05 12:56 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 01Sale57.4930,0001,724,553132,151Jul 01 01:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJul 01Sale57.6950,0002,884,4150Jul 01 01:13 PM